The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment "We are confident that this ...

The U.S. Food and Drug Administration (FDA) announced on June 18, 2025, the release of its proposed method for ranking ...

The US drug regulator has completed a pre-approval inspection at Emcure’s Ahmedabad oncology facility without issuing a Form ...

For a pharmaceutical company, a clean FDA inspection report is crucial for maintaining and expanding its presence in global markets ...

In our world today, aviation unites the many parts of our geography like no other industry. On any given day, one can fly ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

Donanemab was approved by the FDA in July 2024 to treat adults with early symptomatic Alzheimer's disease with confirmed ...

Affiliate content. The best joint supplements for people over 50 in 2025 combine glucosamine, chondroitin, MSM, turmeric, and ...

Boston Scientific announced the FDA approval of expanded labeling for its pulsed field ablation system which now includes ...

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to ...